Interest of Famotidine in Children With Sickle Cell Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 12, 2022

Primary Completion Date

December 12, 2022

Study Completion Date

December 12, 2022

Conditions
Sickle Cell Disease
Interventions
DRUG

Famotidine 400 mg/50 mL

Administration of a suspension of famotidine, 0.5 mg/kg/12h (with a maximum dose of 80 mg/day, regardless of the patient's weight) during 29 days.

Trial Locations (1)

75015

Necker - Enfants malades Hospital; Department of Pediatrics and Infectious Diseases, Paris

All Listed Sponsors
collaborator

INSERM U 1163 - Laboratory of molecular mechanisms of hematologic disorders and therapeutic implications, Paris

UNKNOWN

collaborator

URC-CIC Paris Descartes Necker Cochin

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER